|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100051549 |
|
最近更新日期: Date of Last Refreshed on: |
2022-06-13 11:48:03 |
|
注册时间: Date of Registration: |
2021-09-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
宣肺止嗽合剂真实世界回顾性注册登记研究 |
|
Public title: |
Real-world retrospective registry study of Xuanfei Zhisou compound |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
宣肺止嗽合剂真实世界回顾性注册登记研究 |
|
Scientific title: |
Real-world retrospective registry study of Xuanfei Zhisou compound |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2200006110 |
|
申请注册联系人: |
梁伟杰 |
研究负责人: |
许大庆 |
|
Applicant: |
Liang Weijie |
Study leader: |
Xu Daqing |
|
申请注册联系人电话: Applicant telephone: |
+86 15818874322 |
研究负责人电话:
Study leader's |
+86 13909587382 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liangweijie@kangzhongshidai.com |
研究负责人电子邮件: Study leader's E-mail: |
xudaqing1110@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区西三环南路201号 |
研究负责人通讯地址: |
宁夏银川市兴庆区利群西街2号 |
|
Applicant address: |
201 South Third Ring Road West, Fengtai District, Beijing |
Study leader's address: |
2 Liqun Street West, Xingqing District, Yinchuan, Ningxia |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京康众时代医学研究发展有限公司 |
||
|
Applicant's institution: |
Beijing Kangzhongshidai Medical Research and Development Co., Ltd |
||
|
研究负责人所在单位: |
银川市第一人民医院 |
||
|
Affiliation of the Leader: |
The First People's Hospital of Yinchuan |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LL2021-KY-010 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
银川市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of The First People's Hospital of Yinchuan |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-07 00:00:00 | ||
|
伦理委员会联系人: |
金晓莉 |
||
|
Contact Name of the ethic committee: |
Jin Xiaoli |
||
|
伦理委员会联系地址: |
银川市兴庆区利群西街2号 |
||
|
Contact Address of the ethic committee: |
2 Liqun Street West, Xingqing District, Yinchuan, Ningxia |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
银川市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First People's Hospital of Yinchuan |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
宁夏银川市兴庆区利群西街2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Liqun Street West, Xingqing District, Yinchuan, Ningxia |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
甘肃普安制药股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Gansu Pu'an Pharmaceutical Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
药品不良反应监测 |
||||||||||||||||||||||
|
Target disease: |
Monitoring of adverse drug reactions |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评价真实世界中宣肺止嗽合剂临床应用的安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the safety of the clinical application in the real world. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
在选定的临床试验中心,一定时间内处方中有宣肺止嗽合剂的患者的病历。 |
||||||||||||||||||||||
|
Inclusion criteria |
Medical records of patients with a xuan pulmonary anticough compound were prescribed over time at selected clinical trial centers. |
||||||||||||||||||||||
|
排除标准: |
无。 |
||||||||||||||||||||||
|
Exclusion criteria: |
None. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-10-01 00:00:00至 To 2021-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-10-01 00:00:00 至 To 2021-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |